AIM ImmunoTech Inc. - 8-K Filing
AIM ImmunoTech Inc. filed an 8-K to disclose a June 4, 2026 video presentation highlighting preclinical findings on Ampligen® (rintatolimod) as a potential prophylactic or early-onset antiviral treatment for Ebola virus disease. The company discussed prior Biosafety Level 4 research showing 100% protective survival in a lethal mouse model with early administration of Ampligen and emphasized its immune-modulating mechanism targeting TLR3 pathways. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $AIM